Betting on therapies that haven't yet proven themselves
In the uncertain terrain of early-stage biotechnology, Goldman Sachs and a constellation of hedge funds have quietly accumulated shares in Vir Biotechnology, a company developing therapies for some of humanity's most persistent infectious diseases. Despite steep revenue declines and mounting losses — the hallmarks of a firm still translating scientific promise into commercial reality — institutional investors collectively hold nearly two-thirds of the company, wagering that the distance between today's $4.86 share price and analysts' $17.30 consensus target will one day close. It is a story as old as speculative capital itself: those who can afford to wait, buying what others have grown tired of holding.
- Goldman Sachs expanded its Vir Biotechnology stake by nearly 44 percent in a single quarter, a move that stands out precisely because the company's financials offer little immediate comfort.
- Vir reported a 60.5 percent revenue collapse and missed earnings estimates by 8 cents per share, yet multiple hedge funds — including Woodline Partners, which tripled its position — chose this moment to buy in.
- Analysts at Bank of America, Needham, HC Wainwright, and Evercore have issued buy and outperform ratings, with a consensus price target of $17.30 against a stock trading near $4.86, implying a potential 3.5-fold gain.
- Even as institutions accumulate, company insiders have been quietly selling — Director Vicki Sato and EVP Mark Eisner among them — creating a pointed tension between those who know the pipeline most intimately and those betting on it from the outside.
- The outcome hinges entirely on whether Vir's clinical work in hepatitis delta, hepatitis B, and HIV can survive the long, expensive gauntlet of trials and reach patients — a question no balance sheet can yet answer.
Goldman Sachs made a notable move in the first quarter, expanding its stake in Vir Biotechnology by nearly 44 percent and bringing its total holding to 742,674 shares valued at $4.8 million. The decision signals institutional confidence in a company whose core mission — developing treatments for serious infectious diseases including hepatitis delta, hepatitis B, and HIV — remains scientifically compelling even as its financials tell a harder story.
Goldman was far from alone. Woodline Partners more than tripled its position, while Acadian Asset Management, SCS Capital Management, and Jacobs Levy Equity Management all initiated new stakes during the same period. Institutional investors now collectively own roughly 65 percent of the company, making professional money managers the dominant force in Vir's shareholder base.
The appetite for accumulation is striking given the company's recent results. Vir reported a second-quarter loss of 80 cents per share, missing estimates, while revenue fell 60.5 percent year-over-year to just $1.21 million — less than half of what analysts had expected. Negative margins deep in the thousands of percent reflect the cash-burning reality of early-stage drug development.
Yet the analyst community has grown more bullish, not less. Bank of America upgraded the stock to buy in late August, and firms including Needham, HC Wainwright, Evercore ISI, and Raymond James all carry positive ratings. The consensus price target of $17.30 sits nearly three and a half times above the stock's recent trading price of $4.86.
Against this backdrop of institutional enthusiasm, company insiders have been trimming their holdings. Director Vicki Sato and Executive Vice President Mark Eisner both sold shares in recent months, contributing to roughly $388,000 in insider sales over 90 days. The divergence — insiders selling while hedge funds buy — captures the essential wager at the heart of biotech investing: that clinical progress, not current earnings, will ultimately determine whether the optimism was earned.
Goldman Sachs made a significant bet on Vir Biotechnology in the first quarter, expanding its stake in the immunology company by nearly 44 percent. The investment firm acquired 225,544 additional shares, bringing its total holding to 742,674 shares worth $4.8 million by quarter's end. The move signals institutional confidence in a company that has been struggling operationally, and it's part of a broader pattern of hedge fund accumulation that suggests Wall Street sees something worth buying despite the company's recent stumbles.
Vir Biotechnology develops treatments for serious infectious diseases, with a clinical pipeline focused on hepatitis delta virus, hepatitis B, and HIV, along with preclinical work on influenza, COVID-19, respiratory syncytial virus, and other pathogens. The company's market capitalization sits at $675 million, and its stock has traded as low as $4.16 and as high as $14.45 over the past year. When the stock opened on a recent Wednesday, it was trading at $4.86, well below analyst price targets.
Goldman Sachs was not alone in building a position. Woodline Partners LP expanded its holdings by 245.6 percent, acquiring 331,701 shares to reach a total of 466,737 shares worth $3 million. Acadian Asset Management, SCS Capital Management, and Jacobs Levy Equity Management all initiated new positions during the quarter. Focus Partners Wealth grew its existing stake by 15.3 percent. Institutional investors and hedge funds collectively own 65.32 percent of the company's stock, indicating that professional money managers dominate the shareholder base.
The timing of these purchases is curious given Vir's recent financial performance. In the second quarter, the company reported a loss of 80 cents per share, missing analyst expectations by 8 cents. Revenue came in at $1.21 million, falling short of the $2.38 million consensus estimate and declining 60.5 percent from the same quarter a year earlier. The company posted a negative return on equity of 50.22 percent and a negative net margin of nearly 2,896 percent, reflecting the deep losses typical of early-stage biotech firms burning cash while developing therapies.
Yet Wall Street analysts have grown increasingly optimistic about the company's prospects. Bank of America upgraded Vir from neutral to buy in late August, raising its price target from $12 to $14. Needham & Company and HC Wainwright both maintain buy ratings with targets of $14 and $15 respectively. Evercore ISI initiated coverage with an outperform rating and a $12 target, while Raymond James Financial also began coverage with an outperform rating. Nine analysts rate the stock as a buy, one rates it as hold, and the consensus rating is moderate buy with an average price target of $17.30—nearly 3.5 times the current trading price.
Inside the company, executives have been selling shares. Director Vicki L. Sato sold 22,000 shares on September 2nd at an average price of $4.99, reducing her stake by 1.72 percent but still leaving her with 1.25 million shares worth roughly $6.3 million. Executive Vice President Mark Eisner sold 6,796 shares in mid-July at $5.47 per share, a 5.91 percent reduction in his position. Over the past 90 days, insiders have sold 76,382 shares worth $388,550. Corporate insiders as a group own 16 percent of the company.
The divergence between insider selling and institutional buying creates a familiar tension in biotech investing. Insiders with deep knowledge of the company's pipeline and cash runway are trimming positions, even as hedge funds and major investment banks are accumulating shares, apparently betting that analyst upgrades and the company's clinical development pipeline will eventually drive the stock price toward the $17.30 consensus target. Whether that optimism proves justified will depend on whether Vir's experimental therapies advance successfully through clinical trials and ultimately reach the market.
Citas Notables
Bank of America upgraded Vir from neutral to buy, raising its price target from $12 to $14— Bank of America analyst report, August 27
Nine research analysts have rated the stock with a Buy rating and one has assigned a Hold rating— MarketBeat consensus data
La Conversación del Hearth Otra perspectiva de la historia
Why would Goldman Sachs and other major funds buy into a company losing money at this rate, with revenue collapsing 60 percent year-over-year?
Because they're not investing in Vir's current business—they're investing in its pipeline. Biotech companies routinely operate at massive losses while their drugs move through clinical trials. The question isn't whether Vir is profitable today; it's whether any of its candidates for hepatitis B, HIV, or the other diseases in development will succeed.
But insiders are selling. Doesn't that suggest they're skeptical?
It does raise a flag. When executives and board members trim positions, it can mean they're concerned about near-term prospects or simply need cash. But insider selling at biotech companies is also routine—it's often just portfolio rebalancing or tax planning. The real question is whether they're selling everything or just taking some chips off the table.
The analyst consensus is $17.30, but the stock is at $4.86. That's a massive gap. Is that realistic?
It depends entirely on clinical trial results. If one of Vir's lead candidates shows strong efficacy and safety data, the stock could move sharply higher. Analysts are pricing in the possibility of success. But biotech is binary—drugs either work or they don't. That gap between current price and target price reflects the market's current skepticism, not analyst delusion.
So the hedge funds are essentially betting on clinical trial wins that haven't happened yet?
Exactly. They're betting that the market is undervaluing the probability of success. Whether they're right depends on data we haven't seen yet. That's why it's high-risk capital.
What would make this bet pay off?
Positive Phase 2 or Phase 3 trial results for any of the lead programs. A partnership or licensing deal with a larger pharmaceutical company. Or simply the market reassessing the value of the pipeline as more data emerges. Until then, it's a waiting game.